Table 4.
Steady-state contractile parameters measured in PKA-treated WT and SA myocardial preparations
GrouppCa50nHFmax (mN/mm2)Fmin (mN/mm2)
WT + PKA 
Pre-OM 5.77 ± 0.03 2.04 ± 0.06 17.44 ± 1.68 0.58 ± 0.04 
1.0 µM OM 5.99 ± 0.10 1.07 ± 0.07 (*, P = 0.02) 13.54 ± 0.08 1.52 ± 0.08 
SA + PKA 
Pre-OM 5.79 ± 0.02 2.13 ± 0.13 14.88 ± 0.33 1.54 ± 0.21 
1.0 µM OM 5.92 ± 0.08 1.52 ± 0.32 11.43 ± 2.77 2.19 ± 0.54 
GrouppCa50nHFmax (mN/mm2)Fmin (mN/mm2)
WT + PKA 
Pre-OM 5.77 ± 0.03 2.04 ± 0.06 17.44 ± 1.68 0.58 ± 0.04 
1.0 µM OM 5.99 ± 0.10 1.07 ± 0.07 (*, P = 0.02) 13.54 ± 0.08 1.52 ± 0.08 
SA + PKA 
Pre-OM 5.79 ± 0.02 2.13 ± 0.13 14.88 ± 0.33 1.54 ± 0.21 
1.0 µM OM 5.92 ± 0.08 1.52 ± 0.32 11.43 ± 2.77 2.19 ± 0.54 

pCa50, myofilament Ca2+ sensitivity; nH, cooperativity of force production; Fmax, maximal Ca2+-activated force measured at pCa 4.5; Fmin, Ca2+-independent force measured at pCa 9.0. Values are expressed as mean ± SEM. Data from multiple preparations from each heart were averaged, and six to seven myocardial preparations from three different hearts were used per group. *, Significantly different compared with the corresponding pre-OM group.

or Create an Account

Close Modal
Close Modal